Media Center

PRESS RELEASES

December 20, 2016
REVOLUTION Medicines Raises Additional $25 Million in Series A Financing

READ THE PRESS RELEASE >

December 13, 2016
REVOLUTION Medicines Names Academic Co­Founder, Kevan Shokat, Ph.D., and Senior Advisors, Julian Adams, Ph.D., John Kuriyan, Ph.D., and Trever Bivona, M.D., Ph.D.

READ THE PRESS RELEASE >

June 14, 2016
REVOLUTION Medicines Names Academic Co­Founder, Michael Fischbach,  Ph.D., and Senior Advisor, Eric Gordon, Ph.D.

READ THE PRESS RELEASE >

September 30, 2015
FierceBiotech Names REVOLUTION Medicines as a “Fierce 15” Biotech Company of 2015

READ THE PRESS RELEASE >

June 1, 2015
Rationally Designed Antifungal Compounds that Evade Resistance Reported in Nature Chemical Biology by Scientific Founder of REVOLUTION Medicines

READ THE PRESS RELEASE >

April 9, 2015
REVOLUTION Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson to Board of Directors

READ THE PRESS RELEASE >

March 12, 2015
Major Advances in Synthetic Chemistry Reported in Science by Founding Scientist of REVOLUTION Medicines

READ THE PRESS RELEASE >

March 5, 2015
REVOLUTION Medicines Expands Executive Leadership Team

READ THE PRESS RELEASE >

February 1, 2015
Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases

READ THE PRESS RELEASE >